Introduction {#sec1}
============

The ubiquitin-proteasome system is the central mechanism responsible for the dynamic regulation of protein turnover and the degradation of damaged and misfolded proteins in the eukaryotic cell.^[@ref1],[@ref2]^ The barrel-shaped 20S core of the constitutive proteasome contains three proteolytic subunits with distinct caspase-like (β1), trypsin-like (β2), and chymotrypsin-like (β5) activities. In response to immune and inflammatory stimuli, these subunits get replaced by their isoforms β1i (LMP2), β2i (MECL-1), and β5i (LMP7) to constitute the 20S immunoproteasome which has importance for antigen processing and major relevance for cancer and immune diseases.^[@ref3]^ Subunit specific inhibitors are thus much sought after and a major goal in synthetic approaches of scaffold derivatization and development of chemical probes.^[@ref4],[@ref5]^ In particular, recent insights into the requirement of coinhibition of β2 and β5 for inhibiting the growth of solid tumors^[@ref6]^ and coinhibition of β2i and β5i for the therapy of multiple myeloma^[@ref7]^ and autoimmune diseases^[@ref8]^ pose challenges for subunit-specific coinhibition of constitutive proteasomes and immunoproteasomes. In addition, the proteasome is an attractive target for the development of anti-malarial and anti-mycobacterial drugs.^[@ref9],[@ref10]^ A large number of existing proteasome inhibitor scaffolds are based on natural products of microbial origin including syrbactins, epoxyketones, and β-lactones.^[@ref11]^ However, it remains challenging to detect activity of natural products directly in crude metabolite extracts with thousands of potentially interfering substances including salts and lipids.

In order to meet this challenge, we have envisioned the application of active site-directed chemical probes for the competitive screening of inhibitors. We have recently demonstrated the power of such an approach for the discovery of synthetic inhibitors of quinolone biosynthesis of the human pathogen *Pseudomonas aeruginosa*.^[@ref12],[@ref13]^ Hereby, an active site-directed probe was applied as a tool to profile the inhibition of PqsD, a central enzyme responsible for the biosynthesis of quinolones. Competition experiments with a library of synthetic compounds allowed the detection of those which blocked the probe from accessing and binding to the active site of the enzyme. Since competitive profiling yielded potent inhibitors against PqsD that successfully abrogated quinolone production,^[@ref12]^ we now aimed to explore the applicability of this strategy for the discovery of natural products directly from bacterial culture extracts. We hereby aimed to exploit a chemical probe as a tool for detection and activity-guided purification of natural products as potent proteasome inhibitors. As a proof-of-principle, we selected a Burkholderiales strain which is known to possess a biosynthetic gene cluster for syrbactin production^[@ref14]^ and report here the application of the competitive profiling strategy with an active site-directed probe for the isolation of the three syrbactins luminmycin A, glidobactin A, and glidobactin C. The full potential of this strategy is highlighted by the discovery of a surprising subunit-specific inhibition profile of glidobactin C.

Results and Discussion {#sec2}
======================

Active Site-Directed Proteasome Probe {#sec2.1}
-------------------------------------

We selected syringolin A (**SylA**),^[@ref15]^ a covalently binding Michael-acceptor-type proteasome inhibitor as probe scaffold which is known to target all three proteolytic subunits of the 20S proteasome.^[@ref16]^ To this aim, we isolated **SylA** from an overproducing strain of *Pseudomonas syringae* pv *syringae* ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A and B, [Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)).^[@ref15]^

![Syringolin and competitive profiling strategy. (A) Structures of Syringolin A (**SylA**) and the corresponding **SylP** probe. (B) Covalent Michael-acceptor binding mode of syrbactins on the active site Thr of the proteolytic subunits of the proteasome. (C) Concentration-dependent labeling of constitutive and immunoproteasome. (D) Competitive profiling strategy of natural product extracts for proteasome inhibitors.](oc9b01170_0001){#fig1}

Chemical modification of the compound at its free carboxyl group led to a syringolin probe (**SylP**) comprising a terminal alkyne handle for bioorthogonal modification with a fluorescent reporter tag via the copper(I)-catalyzed alkyne--azide cycloaddition (click chemistry). To test the ability of the **SylP** probe to label the proteolytic subunits of the proteasome, we incubated a purified constitutive proteasome (CP) and immunoproteasome (IP) of human and mouse origin with titrated dose down of **SylP** for 1 h and appended a fluorescent tag via click chemistry with a tetramethylrhodamine (TAMRA) azide. SDS-PAGE and fluorescence scanning revealed labeling of β2/β2i, β5/β5i, and β1i down to 50 nM, while β1 was only labeled down to 0.5 μM ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). The subunits were identified according to their molecular weights and previous assignments.^[@ref17]−[@ref19]^

Competitive Profiling Assays {#sec2.2}
----------------------------

Since labeling of the proteasome was successful, we investigated whether a competitive labeling strategy allowed the detection of the natural product syringolin A from culture supernatants. In short, the purified 20S proteasome was preincubated with the extracts for 1 h followed by treatment with the **SylP** probe and fluorescent labeling via click chemistry. A potent proteasome inhibitor would block the active sites of the proteolytic subunits and exclude probe binding and consequently abolish fluorescent labeling ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D). First, we used purified **SylA** to determine the limit of detection, which was between 5 and 1 μM ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). Since extracts of spent culture media would be concentrated by evaporating the organic solvent, we reasoned that this would allow the detection of syringolin-like proteasome inhibitors in native production levels in the extracts of 6 L culture scale. Indeed, we could confirm this with crude extracts from our syringolin overproducing strain ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). We next aimed to apply our competitive labeling strategy for natural product discovery using a wild-type strain ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D). We selected the Burkholderiales strain DSM 7029 (previously named *Polyangium brachysporum*) which is known to produce glidobactins via a syrbactin biosynthetic gene cluster (BGC) related to the BGC for syringolin biosynthesis of *P. syringae*.^[@ref14]^ Culture supernatants were extracted with ethyl acetate, and competitive screening of RP-HPLC fractions identified multiple fractions that inhibited probe labeling ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A, [Figures S4 and S5](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). Preparative scale fractionation in an activity-guided manner allowed purification of the compounds to homogeneity and elucidation of the chemical structures of the active metabolites by NMR spectroscopy in combination with high-resolution mass spectrometry ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). Three members of the syrbactin family were identified including luminmycin A (**LumA**),^[@ref20]−[@ref22]^ glidobactin A (**GlbA**), and glidobactin C (**GlbC**) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B).^[@ref23]^ Each of the pure compounds was subjected to a dose-down competitive labeling experiment with the probe **SylP** against mouse CP and IP ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, [Figures S7 and S8](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). For some of the compounds, we hereby noticed a surprising subunit selective competition which was particularly interesting for β2 and β5.

![Competitive profiling and identification of proteasome inhibitors. (A) Fractionation of crude metabolite extracts by preparative HPLC and competitive labeling was performed with mouse CP against 1 μM **SylP**. Representative fluorescent gel results of the competitive labeling of fractions A--M are displayed. Active fractions (I--L) were further purified by several rounds of semipreparative HPLC runs and activity was assayed in **SylP** probe competition experiments with mouse CP. Fractions b, d, and e were purified to homogeneity and (B) identified by NMR spectroscopy and mass spectrometry as glidobactin A (**GlbA**), glidobactin C (**GlbC**), and luminmycin A (**LumA**). (C) Dose-down competition experiment of **GlbC** against 1 μM of probe SylP with mouse CP and IP. (D) Subunit specific inhibition assays with fluorogenic peptide substrates shown as examples for β2 and β5 inhibition by **GlbC** in mouse CP and IP.](oc9b01170_0002){#fig2}

Subunit-Selectivity of Isolated Inhibitors {#sec2.3}
------------------------------------------

These selectivities warranted a more detailed investigation of subunit specific inhibition using enzyme assays with fluorogenic peptide substrates. Different syrbactins exhibited interesting selectivities for various subunits of constitutive and immunoproteasome with individual species preferences for proteasomes of mouse or human origin ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D, [Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf), and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Most importantly, however, glidobactins **GlbA** and **GlbC** inhibited β2 and β5, as well as the corresponding immunoproteasome subunits β2i and β5i with exceptional potency largely in the single-digit nanomolar range ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} and [Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). This β2/β5 coinhibition profile is of particular interest, since it has been shown to suppress Nrf1 activation preventing the recovery of proteasome activity. Dual β2/β5 inhibitors are thus considered a hallmark for the treatment of breast cancer and multiple myeloma.^[@ref6],[@ref7],[@ref24]^ While unique structural features of the subunits β1, β1i, β5, and β5i have allowed the development of selective inhibitors,^[@ref25]−[@ref27]^ discriminating β2 and β2i has remained a challenge due to their high structural similarity.^[@ref28]^ Just recently, the first synthetic inhibitors based on epoxyketones with up to 45-fold selectivity for β2i were reported.^[@ref29]^ To our surprise, we found that **GlbA** and **GlbC** displayed the highest selectivity for mouse β2i with IC~50~ values of 1.4 and 15 nM, respectively, while β2 of the constitutive proteasome was almost unaffected at concentrations up to 1 μM (β2/β2i \> 714, **GlbA**; β2/β2i \> 66, **GlbC**).

###### IC~50~ Values of Isolated Compounds in mol/L Were Determined Using the Hydrolysis of Fluorogenic Substrates for the 20S Immunoproteasomes (IP) or Constitutive Proteasomes (CP) of Human or Mouse Origin[a](#tbl1-fn1){ref-type="table-fn"}

  activity/species                                                       proteasome              **SylA**                **SylP**                **LumA**                **GlbA**                 **GlbC**
  ---------------------------------------------------------------------- ----------------------- ----------------------- ----------------------- ----------------------- ------------------------ -----------------------
  Chymotrypsin-Like Activity (β5/β5i)[b](#t1fn1){ref-type="table-fn"}                                                                                                                             
  human                                                                  CP                      (1.8 ± 1.1) × 10^--7^   (1.0 ± 0.8) × 10^--8^   (3.9 ± 0.2) × 10^--8^   (3.6 ± 1.1) × 10^--9^    (2.9 ± 2.2) × 10^--9^
  IP                                                                     (2.4 ± 1.9) × 10^--6^   (3.6 ± 1.8) × 10^--8^   (1.6 ± 0.6) × 10^--6^   (2.5 ± 1.9) × 10^--8^   (7.1 ± 5.3) × 10^--9^    
  mouse                                                                  CP                      (5.9 ± 1.6) × 10^--8^   (2.1 ± 0.0) × 10^--9^   (3.2 ± 2.9) × 10^--8^   (6.5 ± 0.8) × 10^--10^   (2.7 ± 3.4) × 10^--9^
  IP                                                                     (1.8 ± 2.0) × 10^--7^   (3.2 ± 1.9) × 10^--9^   (8.9 ± 0.6) × 10^--9^   (1.1 ± 0.1) × 10^--9^   (1.3 ± 0.7) × 10^--9^    
  Trypsin-like activity (VGR) (β2/β2i)[b](#t1fn1){ref-type="table-fn"}                                                                                                                            
  human                                                                  CP                      n.i.                    (1.4 ± 1.8) × 10^--7^   (2.6 ± 0.8) × 10^--7^   (1.5 ± 1.5) × 10^--8^    (2.4 ± 2.8) × 10^--8^
  IP                                                                     (6.7 ± 7.5) × 10^--7^   (1.6 ± 0.2) × 10^--8^   (1.7 ± 1.6) × 10^--7^   (4.2 ± 0.8) × 10^--8^   (2.5 ± 2.0) × 10^--9^    
  mouse                                                                  CP                      n.i.                    n.i.                    n.i.                    n.i.                     n.i.
  IP                                                                     n.i                     (1.1 ± 1.4) × 10^--7^   n.i.                    (1.4 ± 1.6) × 10^--9^   (1.5 ± 1.3) × 10^--8^    
  Caspase-Like Activity (β1)[b](#t1fn1){ref-type="table-fn"}                                                                                                                                      
  human                                                                  CP                      n.i.                    n.i.                    n.i.                    n.i.                     n.i.
  mouse                                                                  CP                      (5.0 ± 7.0) × 10^--5^   (2.1 ± 0.5) × 10^--7^   n.i.                    n.i.                     n.i.
  LMP2 Activity (β1i)[b](#t1fn1){ref-type="table-fn"}                                                                                                                                             
  human                                                                  IP                      (7.6 ± 0.0) × 10^--7^   (1.7 ± 0.6) × 10^--7^   n.i.                    n.i.                     n.i.
  mouse                                                                  IP                      (2.8 ± 1.0) × 10^--8^   (2.2 ± 1.5) × 10^--8^   n.i.                    (2.5 ± 0.8) × 10^--7^    n.i.

IC~50~ values ± SD of two series of four independent experiments are indicated.

Chymotrypsin-like (Suc-LLVY-AMC), trypsin-like (Bz-VGR-AMC), caspase-like (Z-LLE-βNA), or LMP2 (Ac-PAL-AMC) activity. n.i.: inhibition below 50% at 1 μM.

This selectivity in combination with the high potency is unprecedented and even more surprising to be found for microbial natural products. In contrast to the mouse proteasome, no such selectivity was found between human β2 and β2i, indicating distinct substrate binding affinities of these proteasome subunits in mouse and human. Interestingly, **LumA**, which corresponds to **GlbA** lacking a hydroxyl group at the ring, poorly inhibited β2 and β2i of human and mouse at orders of magnitude higher concentrations.

Cell Permeability {#sec2.4}
-----------------

Finally, we were interested in the cell permeability of the different syrbactins which we investigated in live LCL721.145 cells using the cell-permeable substrate MeO-Suc-GLF-AMC to quantify the chymotrypsin-like activity. Hereby, **SylA** failed to inhibit chymotrypsin-like activity up to 1 μM, indicating poor cell permeability. Surprisingly, the more hydrophobic **LumA** and **GlbA** also remained inactive in live cell experiments.

However, **GlbC** which differs from **GlbA** only by encompassing two additional methylene groups in its acyl-chain considerably inhibited substrate cleavage in live cells, suggesting that its slightly increased chain length sufficiently enhanced membrane penetration ([Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)).

Activity in Cell-Based Assays {#sec2.5}
-----------------------------

Consequently, we further explored the activity of **GlbC** in live cells. Mouse fibrosarcoma MC57 cells treated for 6 h with **GlbC** accumulated ubiquitin conjugates in concentration dependence with even slightly better efficiency as compared to the synthetic aldehyde proteasome inhibitor MG132 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A and B). In addition, the pro-inflammatory cytokine response upon lipopolysaccharide (LPS) stimulation of mouse splenocytes was inhibited by **GlbC** treatment ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}C). These results indicate potent inhibition of CP and IP in live cells. Finally, we also investigated the anticancer potential of **GlbC** in the human breast cancer cell lines BT-549, MDA-MB-231, and MDA-MB-361 for which β2/β5 coinhibition is particularly required. Indeed, 0.25 μM of **GlbC** blocked proliferation, and higher concentrations led to cancer cell death ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}D, [Figure S11](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). In order to test whether **GlbC** alters T cell proliferation differently in immunoproteasome-proficient wild-type T cells and immunoproteasome-deficient MECL-1^--/--^/LMP7^--/--^ T cells, cell division of CD4^+^ T cells was analyzed after T cell receptor (TCR) stimulation ([Figure S12](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)). **GlbC** inhibited T cell proliferation in a dose-dependent manner. However, no difference between immunoproteasome-proficient and -deficient T cells could be observed. Although **GlbC** showed selectivity for mouse β2i ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), this result is not unexpected since β2i inhibition by **GlbC** is less potent (IC~50~ = (1.5 ± 1.3) × 10^--8^) and since it has been shown that inhibition of LMP7 together with LMP2 or MECL-1 is important to alter T cell differentiation and cytokine secretion.^[@ref8],[@ref30]^ However, similar selectivity of **GlbC** for LMP7 and β5 as well as for LMP2 and β1 was observed in this study ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Nevertheless, it is remarkable that the proliferation inhibition of CD4^+^ T helper cells by **GlbC** is much lower than the inhibition by bortezomib, although the proliferation inhibition of the breast carcinoma line MDA-MB-231 by **GlbC** ([Figure S11](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf)) is similar to that of bortezomib.^[@ref6]^ This result suggests that the β2/β5 selectivity of **GlbC** may enable a strong anticancer effect accompanied by less immunotoxicity than bortezomib.

![Live cell activity assays with **GlbC**. (A) The proteasome degrades ubiquitinated proteins. (B) These ubiquitin--protein conjugates accumulate upon **GlbC** treatment as visualized by Western blot analysis with mAb FK2. Loading control: GADPH; positive control: proteasome inhibitor MG132. (C) ELISA analysis of IL-6 in the culture supernatant of C57BL/6 mouse splenocytes treated with **GlbC**. Positive control: β1i/β5i specific inhibitor ONX 0914. (D) Cell count after 2-day treatment of breast cancer cell line BT-549 with **GlbC**. The dotted line corresponds to the number of cells seeded on day 0.](oc9b01170_0003){#fig3}

These results demonstrate the strength of competitive profiling for the discovery of proteasome inhibitors and activity-guided fractionation of crude metabolite extracts. The value of direct assays to discover proteasome inhibitors from complex microbial metabolite mixtures has also been shown by an NMR-based technique using a ^13^C-labeled substrate that led to the isolation of the syrbactin cepafungin I.^[@ref31]^ Although the family of syrbactins has been known for decades,^[@ref20],[@ref23],[@ref32]^ our understanding of their specificity for subunits of the 20S proteasome has so far been incomplete.^[@ref33]^ A syringolin-based probe directly linked with fluorophore has been useful for 20S proteasome labeling in leukemia cell lines,^[@ref18]^ as well as for characterizing the subunit-selectivity of **SylA** and for noninvasive imaging in live cells of *Arabidopsis*.^[@ref16]^ A synthetic **SylA-GlbA** hybrid has been reported which inhibited all three subunits of the proteasome of tumor cell lines.^[@ref34],[@ref35]^ This chimera consisted of a **SylA** core combined with the tail of **GlbA**. Our results show that the ring hydroxyl group of the **GlbA/C** core is important for efficacy in β2/β2i inhibition, and efficacy is reduced when the hydroxyl group is missing (**LumA**). In contrast, the **SylA** core exhibits increased β1/β1i binding that can be partially modulated by the hydrophobicity of the tail (**SylP**). Thus, the selectivity of **GlbA/C** has so far been missed and we present here the first account demonstrating that the inhibition profile and efficacy of **GlbA** and **GlbC** are markedly different from those of **SylA** and **LumA**.

Conclusions {#sec3}
===========

In summary, glidobactin C exhibits a highly interesting β2/β5 subunit coinhibition profile that in combination with its cell permeability makes glidobactin C a promising anticancer drug candidate and a tool for subunit-specific proteasome inhibition in live cells. So far, it has been shown that the combination of β5/β5i inhibitors with a β2/β2i inhibitor inhibits the growth of cancer cell lines of breast, lung, kidney, and ovarian carcinoma,^[@ref6]^ but to the best of our knowledge, an inhibitor like **GlbC** that inhibits the active centers of both human β5/β5i and β2/β2i subunits at single-digit nanomolar potency has not been reported to date and holds great potential for cancer therapy. Hence, it will be pertinent to test the effect of **GlbC** on the growth of cancer cell lines derived from other solid tumors of humans. These results demonstrate that competitive profiling using active site-directed chemical probes is a suitable strategy to identify and isolate proteasome inhibitors from complex microbial metabolite mixtures. Furthermore, minor structural differences in native syrbactins have a major impact on subunit and species selectivity of these proteasome inhibitors. A major advantage of the **SylP** probe developed herein is that, compared to the natural proteasome inhibitor **SylA**, it is only minimally extended by introduction of the alkyne moiety affording facilitated entry into the proteolytic central chamber of the 20S proteasome. Nevertheless, bulky fluorescent or other labels can subsequently be attached via click reaction after the proteasome subunits have been disassembled by denaturation. Our results indicate that the syrbactin core largely determines subunit selectivity, while the tail modulates efficacy and cell permeability. These results indicate that structural diversification of syrbactins within a single producer species may be driven by functional specialization. This again may represent a strategy for evolutionary adaptation to complex ecological interactions with multiple different eukaryotic hosts, competitors, or predators.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acscentsci.9b01170](https://pubs.acs.org/doi/10.1021/acscentsci.9b01170?goto=supporting-info).Additional data, methods, and supplementary figures including probe synthesis, fluorescent gels of proteasome labeling experiments, competitive profiling, isolation methods, characterization of isolated natural products, NMR spectra, proteasome inhibition assays, Western blot analysis of ubiquitin accumulation, ELISA assay of cytokine response upon lipopolysaccharide (LPS), cancer cell viability assays, and T-cell proliferation assays ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acscentsci.9b01170/suppl_file/oc9b01170_si_001.pdf))
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